BioCentury | May 9, 2018
Distillery Therapeutics

Cancer

...embryo studies suggest inhibiting FZD8 could help treat prostate cancer. In patient samples, levels of FZD8...
...of the cell lines, two tool compound FZD8 inhibitors decreased migration compared with vehicle. The FZD8-targeting...
...FZD8, in Phase I testing for solid tumors and liver, ovarian and pancreatic cancers. TARGET/MARKER/PATHWAY: Frizzled homolog 8 (FZD8)...
BioCentury | May 2, 2018
Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Tool compounds; structural analyses Structural analysis of a peptide inhibitor bound to the cysteine-rich domain (CRD) of FZD7 could guide the development of small molecule FZD7 inhibitors, and the peptide could be used to...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...two other cancer stem cell programs -- its anti- FZD7 mAb vantictumab and its anti- FZD8-Fc...
...Delta-like 4 FAK - Focal adhesion kinase FZD7 - Frizzled homolog 7 FZD8 - Frizzled homolog 8...
BioCentury | Apr 10, 2017
Clinical News

OncoMed's demcizumab fails Phase II pancreatic cancer trial

...steps for all of its pipeline assets. The company does not market any drugs. Jaime De Leon anti-Frizzled demcizumab Fzd8-Fc ipafricept OMP-18R5 OMP-21M18 OMP-54F28 vantictumab Bayer...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer Cell culture, mouse and patient sample studies suggest anti- FZD5 mAbs could help treat pancreatic, colorectal, and other RNF43 -mutant cancers. In four RNF43-mutant human pancreatic ductal adenocarcinoma (PDAC) cell...
BioCentury | Nov 17, 2016
Clinical News

Vantictumab: Interim Ph Ib data

Interim data from 21 evaluable patients in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV vantictumab on days 1 and 15 of each 28-day cycle plus Abraxane nab-paclitaxel and gemcitabine led to an...
BioCentury | Nov 17, 2016
Clinical News

Ipafricept: Interim Ph Ib data

...see BioCentury, June 21, 2010 ). OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Ipafricept (Fzd8-Fc...
BioCentury | Nov 15, 2016
Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Cell culture and mouse studies suggest inhibiting FZD1 , FZD2 and/or FZD7 could help treat Clostridium difficile infection (CDI). In a human cell line treated with TcdB , knockout of FZD1, FZD2 or FZD7 decreased...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
BioCentury | Jun 6, 2016
Clinical News

Ipafricept: Phase Ib data

...see BioCentury, June 21, 2010). OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Ipafricept ( Fzd8-Fc...
Items per page:
1 - 10 of 41